July 16, 2013 / 3:51 PM / 4 years ago

U.S. FDA cancels advisory committee on Merck's drug sugammadex

July 16 (Reuters) - The U.S. Food and Drug Administration cancelled an advisory committee meeting set for Thursday to discuss Merck & Co’s sugammadex, a drug designed to reverse the effects of muscle-relaxants used during surgery.

The FDA declined to say why the meeting had been cancelled, referring questions to Merck. A spokeswoman for Merck did not immediately return a phone call or email seeking comment.

Sugammadex is the first in a new class of drugs, known as selective relaxant binding agents, that are designed to reverse the effects of the muscle-relaxants rocuronium and vecuronium.

Merck acquired sugammadex when it bought Schering-Plough for $41 billion in 2009. (Reporting by Toni Clarke in Washington; Editing by Gerald E. McCormick)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below